研究失败导致鲁伐他的神经分泌终止发展

Neurocrine Biosciences (NASDAQ:NBIX) has halted development of luvadaxistat due to disappointing results from a Phase 2 study of the drug in the treatment of cognitive impairment in schizophrenia patients.

The company said the study failed to meet its primary endpoint or replicate the cognitive endpoints data seen in an earlier study called INTERACT, according to a statement.

Neurocrine attributed the study failure in part to “the large variability seen in the cognitive measures across the population studied and a potential imbalance in the baseline characteristics of subjects enrolled across the treatment arms.”

Rather than pursuing further development of the drug, Neurocrine plans to focus on advancing NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder into Phase 3 testing.

In late August, Neurocrine reported positive Phase 2 data for NBI-1117568, which it said supported advancement of the drug into Phase 3 trials in early 2025.